Biotech; Pharma; Human Resources · medium ·
Biopharma's CRL scrutiny is creating an expertise constraint
The biopharmaceutical industry is experiencing a surge in demand for clinical and regulatory leaders with proven experience in navigating complex FDA Complete Response Letters (CRLs) for drug-device combination products. This talent need is driven by increasing FDA scrutiny on pharmacokinetic variability and the heightened risk associated with novel drug delivery systems, compelling companies to proactively manage regulatory hurdles.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.
Part of the Technology Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.
Part of the People & HR Opportunity Outlook, Korim's collection of emerging opportunities in this sector.